Abbott Laboratories Issues Bonds to Fund Exact Sciences Acquisition

Abbott Laboratories is set to issue corporate bonds in up to eight segments to finance its approximately $21 billion acquisition of Exact Sciences Corp., a company specializing in cancer screening. Bloomberg posted on X, highlighting the strategic move by Abbott to expand its portfolio in the healthcare sector. The acquisition aims to enhance Abbott's capabilities in the early detection of cancer, aligning with its broader strategy to strengthen its presence in the medical diagnostics field. The bond sale is expected to attract significant interest from investors, given the scale and impact of the acquisition on Abbott's future growth prospects.